Cancer Education and Research Institute
Worldwide Access to Research, High-Quality Care, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2021
      • Press Releases 2020
      • Press Releases 2019
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • Patient Education
    • All about cancer
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types-Education
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
    • CERI Personalized Patient Program
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us

The Journal of Simplified Cancer Research (JSCR) - New Article Release

Tweet
Follow @canceredinst

The General Effects of Aspirin and Cancer Clinical Trials
By Ms. Elana Meer (Princeton University) | CERI Research Team
More details of this article can be found in our JSCR - November 2014 Issue

The General Effects of Aspirin
Inflammatory Responses
One of the major hallmarks of cancer is inflammation, part of the body’s immune response to foreign pathogens, damaged cells, and other irritants. As a mechanism to heal damaged tissue and get rid of infection, inflammation tends to involve greater blood flow to the tissue in a particular region causing increased temperature, redness, swelling and pain. As part of the immune response, inflammation also increases levels of mitosis, the cell division step of cell growth. With the production of more cells during mitosis, there is a greater probability of cancerous mutations that may lead to significant tumor growth. Similarly, during inflammation, reactive oxygen species (ROS), agents capable of damaging DNA, are released into the blood stream and surrounding cells. Likewise, apoptosis - the programmed death of damaged cells - tends to be significantly reduced in inflamed tissues. Therefore, cells with genetic mutations may develop into full cancers instead of being naturally killed off. Overall, chronic inflammation can have deleterious effects, as it may cause the formation of new blood vessels, increase the chance of DNA mutations, and ultimately promote tumor growth.

Aspirin mechanisms
Aspirin Mechanisms
Over the past couple of years, Aspirin has come into discussion as a potential cancer therapy. Aspirin blocks inflammation by inhibiting the activity of COX-1 and COX-2 enzymes, important in mitigating the inflammatory immune response to tissue injury or infection.  By blocking COX-2 enzyme, also involved in pain, aspirin has additional benefits associated with pain reduction. Through this mechanism, Aspirin seems to be a promising treatment for cancer prevention, although the experimental results are not definitive. Research has shown that regularly taking aspirin may reduce risk of death for gastrointestinal, bowel, colorectal, lung, prostate, ovarian, and even brain cancers. Other studies have shown that large doses of aspirin, taken consistently for multiple years, is necessary to have such a positive cancer reduction effect. This may have dangerous implications, as aspirin can cause side effects of bleeding in the stomach and gut that increase with age and with quantity of aspirin taken. There are still outstanding questions: At what age people should start and stop taking aspirin? What should the dosage be? What risk factors may exist and how are they determined?

Clinical Trials and Current Research
In addition to independent research studies, the National Cancer Institute is funding clinical trials to show how aspirin reduces the recurrence of polyps, extra pieces of tissue that grow on the lining of certain organs that can become cancerous. Early observational studies have shown that people who consistently take aspirin are less likely to get colorectal adenomas, abnormal growths that may launch the development of colorectal cancers. The ASPREE Cancer Endpoint Study (ACES) examines the effect of a low dose of aspirin on recurrent cancers, and is in its phase 4 stage of development. The National Cancer Research Institute is also in its phase II clinical trial to determine the effect of combined therapies of Difluoromethylornithine (DFMO/ eflornithine) with aspirin to see if there is a lower recurrence rate of cancers, specifically colorectal cancer. Similarly, the ASCOLT trial is testing to see if 200 mg of aspirin per day for 3 years can improve “disease-free or overall survival” in patients previously treated for colorectal cancer. The ASPREE trial is currently enrolling healthy participants, aged 65 years or older to determine whether the overall benefits of taking aspirin for 5 years, such as prevention of heart disease, stroke, cancers, etc, can outweigh the associated risks. Many studies explore similar ways of using aspirin as an isolated mechanism for cancer therapies, as well as a combined method of reducing the likelihood and reoccurrence of cancerous growths.

Aspirin mechanisms



Aspirin and cancer clinical trials

If you think taking aspirin as a preventative measure might be appropriate, schedule a conversation with your doctor.

For more information about clinical trials visit: 
http://www.cancer.gov/cancertopics/research-updates/2014/aspirin http://www.cancer.gov/clinicaltrials/search/view?cdrid=754049&version=HealthProfessional&protocolsearchid=13373041

Resources:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994795/
http://www.cancer.gov/cancertopics/research-updates/2014/aspirin http://www.cancer.gov/clinicaltrials/search/view?cdrid=754049&version=HealthProfessional&protocolsearchid=13373041

    Help us to serve you better!

Submit
The Journal of Simplified Cancer Research (JSCR) is the official journal of Cancer Research Simplified. For only $4.99 per monthly issue, [or a discounted $49.99 per year], you can gain digital access to straightforward information and articles on cancer news, diagnosis, prevention, treatment, and clinical trials. Fill out the form, make your payment, and you'll receive your copy right in your inbox! To get your copy now on The Journal of Simplified Cancer Research (JSCR) page.

Yes, I'd like to help CERI continue saving lives!

Donate

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2022 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®